IP Library › Granted Patent US 11,098,294
Granted Patent B2
US 11,098,294 · App. 16/818,001 · Granted Aug 24, 2021

Anti-inflammatory peptides and composition comprising same

Inventors: Sang Jae Kim (Seoul, KR); Kyung Hee Kim (Seongnam-si, KR); Kyu-Yong Lee (Seongnam-si, KR); Seong-Ho Koh (Seongnam-si, KR); Bum Joon Kim (Seongnam-si, KR); Hyun-Hee Park (Seongnam-si, KR); Sung Jin Huh (Seongnam-si, KR); Woo Jin Lee (Seongnam-si, KR); Hwain Jang (Seongnam-si, KR); Jung Soon Ha (Seongnam-si, KR)
Assignee: GemVax & KAEL Co., Ltd.
C12N9/1276A23L33/18A61K38/45A23V2002/00C12Y207/07049Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,098,294
App. No.
16/818,001
Granted
Aug 24, 2021
Kind
B2
Abstract

The present invention relates to methods of treating or preventing inflammation with a peptide having anti-inflammatory activity, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 101. According to the present invention, the peptide of SEQ ID NO: 101 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the method comprising administration of the peptide of this invention can be used in anti-inflammatory pharmaceutical or cosmetic applications, in turn, treating and preventing a variety of different types of inflammatory diseases.

Claims (5)

1. A method of treating or preventing inflammatory disease in a patient, comprising administering to the patient an isolated peptide having anti-inflammatory activity, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 101.

2. The method according to claim 1 , wherein the inflammatory disease is selected from a group that consists of general or localized inflammatory disease; gastro-intestinal related diseases; dermal related diseases; vascular related disease; respiratory diseases; bone, joint, muscle, and connective tissue related diseases; urogenital disorders; central or peripheral nervous system related diseases; virus; and autoimmune diseases.

3. The method according to claim 1 , wherein the daily dose of the peptide is about 0.1 μg/kg/day to 1 g/kg/day.

4. A method of treating or preventing skin inflammation comprising administering an isolated peptide having anti-inflammatory activity, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 101.

5. The method according to claim 4 , wherein the daily dose of the peptide is 0.1 μg/kg/day to 1 g/kg/day.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2020
From: KIM, SANG JAE; KIM, KYUNG HEE; LEE, KYU-YONG; KOH, SEONG-HO; KIM, BUM JOON; PARK, HYUN-HEE; HUH, SUNG JIN; LEE, WOO JIN; JANG, HWAIN; HA, JUNG SOON
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 053741/0487 →
Priority Claims (6)
KR 10-2012-0079096 · Jul 20, 2012 · national
KR 10-2012-0089161 · Aug 14, 2012 · national
KR 10-2012-0089162 · Aug 14, 2012 · national
KR 10-2012-0089167 · Aug 14, 2012 · national
KR 10-2012-0104144 · Sep 19, 2012 · national
KR 10-2012-0104207 · Sep 19, 2012 · national
Continuity (2)
Division 14400322
Related Publication 20200208127A1 · Jul 2, 2020